12 institutions will conduct Phase II trial of Alzheimer's gene therapy

02/1/2010 | American City Business Journals

Emory University is one of 12 institutions across the U.S. that will participate in a midstage clinical trial of CERE-110, an experimental gene therapy for Alzheimer's disease. The study will involve injecting the treatment in the brain of patients with mild to moderate Alzheimer's to stimulate brain cells to continuously produce nerve growth factor proteins.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD